19:27:03 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaOB Match
ContextVision är ett medicinteknologiskt bolag. Bolaget specialiserar sig inom bildanalys och artificiell intelligens. Bland bolagets produkter återfinns avancerade bildförbättringsprogram för ultraljud, MRI, röntgen samt mammografi. Programvarorna används idag av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1983 och har sitt huvudkontor i Stockholm.


2023-02-16 Bokslutskommuniké 2022
2022-10-20 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-04 Årsstämma 2022
2022-04-21 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-12-10 Extra Bolagsstämma 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning CONTX 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-19 Split CONTX 1:10
2020-08-13 Kvartalsrapport 2020-Q2
2020-08-05 Extra Bolagsstämma 2020
2020-05-07 Ordinarie utdelning CONTX 0.00 NOK
2020-05-06 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CONTX 0.00 NOK
2019-05-08 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-11 Ordinarie utdelning CONTX 0.00 NOK
2018-05-09 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-11 Ordinarie utdelning CONTX 0.00 NOK
2017-05-10 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-04-21 Ordinarie utdelning CONTX 0.00 NOK
2016-04-21 Kvartalsrapport 2016-Q1
2016-04-20 Årsstämma 2016
2016-02-18 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-04-23 Kvartalsrapport 2015-Q1
2015-04-23 Ordinarie utdelning CONTX 0.00 NOK
2015-04-22 Årsstämma 2015
2015-02-19 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-12 15-7 2014
2014-04-24 Ordinarie utdelning CONTX 0.00 NOK
2014-04-24 Kvartalsrapport 2014-Q1
2014-04-23 Årsstämma 2014
2014-02-20 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-06-13 Ordinarie utdelning CONTX 0.00 NOK
2013-06-12 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-21 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-23 Kvartalsrapport 2012-Q2
2012-06-14 Ordinarie utdelning CONTX 0.00 NOK
2012-06-13 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-23 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-06-10 Ordinarie utdelning CONTX 0.00 NOK
2011-06-09 Årsstämma 2011
2011-04-28 Kvartalsrapport 2011-Q1
2011-02-17 Bokslutskommuniké 2010
2010-10-21 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-06-04 Ordinarie utdelning CONTX 0.00 NOK
2010-06-03 Årsstämma 2010
2010-04-21 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-10-22 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-23 Kvartalsrapport 2009-Q1
2008-06-06 Ordinarie utdelning CONTX 1.50 NOK
2021-10-21 08:00:00

STOCKHOLM – October 21, 2021 – ContextVision, a medical technology software company specializing in image processing and decision support tools within digital pathology, has decided to build its first fully digital pathology laboratory – thus confirming its strong dedication to advancing digitalization within pathology, for the best of both patients and the medical profession.

Sales in the third quarter reached 26.0 MSEK (22.0), a 7% increase compared with the previous quarter, and an increase of 18% versus last year's corresponding quarter. EBITDA ended at 5.7 MSEK and the cash position was 48.1 MSEK at the end of the quarter.

Building our own modern digital pathology lab would enable us to advance faster and create greater value for patients, clinicians and pathologists. We have investigated this path in a research project for quite some time. The need is unquestioned, and the potential is huge, making this a game changer for ContextVision,” says CEO Fredrik Palm of ContextVision.

Lab manager already recruited
INIFY Prostate will be the core machine learning technology intended to be seamlessly integrated in the lab. Statistical process control over the entire chain, from specimen delivery to diagnostic report, will enable an innovative pathology service with the highest efficiency and diagnostic quality. The lab will focus on prostate cancer diagnosis as a start, and the first steps are already taken.

Negotiations have been initiated regarding lab premises in Stockholm in proximity to world-class medical research and healthcare. We have already recruited an experienced lab manager, a vital team member in the construction and operation of the lab, who will join us full-time in January 2022,” says Palm.

In connection with this, the board of directors has instructed the management to create a subsidiary for the intended laboratory operations.

INIFY development
Results from the company’s multicenter study in EU were presented at the European Congress of Pathology in August. The study showed that INIFY Prostate is robust across the four different sites involved, and that the pathologists and surrounding staff were very positive to the product’s performance.

Recently announced, first results from the ongoing studies in the United States were presented at the Pathology Vision congress in Las Vegas. These showed an impressive sensitivity in detecting cancer areas, including very small areas of ≤1mm. The study was conducted with two labs to prove the robustness against differences in hardware setups.

Additionally, results from an ongoing research project in Sweden within colorectal cancer were presented. They indicated that the pathologist could perform assessments significantly faster with maintained diagnostic accuracy, when using our prototype.

Strong sales
Medical Imaging business continues on its positive path. At long last, the world is gradually reopening, enabling staff to travel and meet present and new potential customers. Exceptional orders in America took the company to a third quarter sales record. Sales in America are expected to grow in comparison with historical numbers, but will most likely become more evenly distributed during the upcoming year.

Strong sales continue to give signals of a stepwise return to our expected pre-pandemic growth plan. With important organization additions strengthening our team, we look forward to the fourth quarter and a strong year finish, while preparing for a successful 2022,” says Palm.

The company will hold a presentation and Q&A web conference on Oct 22nd at 09:30-10:15 CEST – use the link below for registration.


For further information, please contact ContextVision's CEO, Fredrik Palm, at fredrik.palm@contextvision.se, or visit www.contextvision.com


About ContextVision
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X- ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

ContextVision has built up a business unit for the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools, and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation article 7 and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was submitted for publication, through the agency of the contact persons set out above on 21 October 2021.